Lupin announces achievement of key milestones for its MEK inhibitor compound


Lupin today announced the achievement of key milestones for Lupin’s MEK inhibitor compound (LNP3794) that is planned for development by Boehringer Ingelheim in combination as potential targeted therapy for patients with difficult-to-treat cancers.

As part of the agreement, Lupin has received payment of USD 50 million from Boehringer Ingelheim for achievement of key milestones.

Lupin was quoting at Rs 1,203.40, up Rs 7.65, or 0.64 percent on the BSE.

News source:- Livemint

For Enquiry Fill The Form

    *Note:- Please provide a valid Email Id to receive OTP from

    Facebook Iconfacebook like buttonYouTube IconTwitter Icontwitter follow button